Table 2 Treatable genetic variants and level of clinical utility
Patient | Gene | Tumor genetic variants (copy number) | Treatment options | ||
|---|---|---|---|---|---|
1° tumor | 2° tumor | Druga | Level of clinical utility | ||
P1 | EGFR | E746_A750delELREA (1) | E746_A750delELREA (1) | Gefitinib | Level A |
P2 | EGFR | E746_A750delELREA (1) | E746_A750delELREA (2) | Gefitinib | Level A |
P3 | EGFR | E746_A750delELREA (6) | E746_A750delELREA (5) | Gefitinib | Level A |
Amplification | Amplification | Erlotinib | Level B | ||
P4 | EGFR | L747_A750delinsP (1) | L747_A750delinsP (1) | Gefitinib | Level A |
P5 | EGFR | E746_A750delELREA (0.1) | E746_A750delELREA (2) | Gefitinib | Level A |
P6 | EGFR | E746_A750delELREA (1) | E746_A750delELREA (9) | Gefitinib | Level A |
No amplification | Amplification | Erlotinib | Level B | ||
TP53 | Negative | Q331X (2) | AZD1775 | Level D | |
P7 | EGFR | L858R (2) | L858R (3) | Gefitinib | Level A |
P8 | EGFR | L858R (5) | L858R (4) | Gefitinib | Level A |
P9 | EGFR | L858R (5) | L858R (6) | Erlotinib | Level A |
Amplification | Amplification | Erlotinib | Level B | ||
ATM | W3052X (2) | W3052X (2) | Olaparib | Level D | |
P10 | EGFR | Negative | L858R (4) | Osimertinib | Level A |
CDK4 | No amplification | Amplification (17) | Abemaciclib | Level B | |
P11 | EGFR | Negative | L858R (2) | Gefitinib | Level A |
P12 | EGFR | G719S (5) | G719S (5) | Osimertinib | Level B |
Amplification | Amplification | Erlotinib | Level B | ||
TP53 | R196X (2) | R196X (2) | AZD1775 | Level D | |
P13 | EGFR | L861Q (2) | L861Q (3) | Gefitinib | Level A |
TP53 | R248W (2) | R248W (2) | AZD1775 | Level D | |
P14 | ALK | Fusion (0.3) | Fusion (0.2) | Crizotinib | Level A |
P15 | TP53 | F134Pfs (1) | F134Pfs (1) | AZD1775 | Level D |
FGFR1 | Amplification (5) | Amplification (6) | Dovitinib | Level D | |
P16 | FGFR3 | R248C (0.1) | Negative | Dovitinib | Level D |
KRAS | Negative | G12D (1) | Cobimetinib | Level D | |
P17 | KRAS | G12C (1) | G12C (1) | AMG-510 | Level B |